secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2026-06-09T20:35:35+00:00
Accession:  0001193125-26-263873
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics increases authorized common stock from 300M to 450M shares after stockholder approval
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common shares to 450M from 300M, a 50% increase.
- Vote: 170,323,683 for, 909,020 against, 23,821 abstain; amendment effective June 9, 2026.
- Directors elected: Douglas S. Ingram and Claire Mazumdar each received >120M votes for; 24.2M broker non-votes.
- Non-binding say-on-pay approved: 143,849,919 for, 3,154,118 against, 51,787 abstain.
- Ratification of Ernst & Young as independent auditor for FY2026: 171,030,133 for, 204,449 against, 21,942 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526263873/0001193125-26-263873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526263873/rlay-20260609.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-263873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer